US Patent Granted for Dimerix New Asset DMX-652
Filed with ASX · · 3 pages · English
Story so far
Earlier from Dimerix
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
- Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
- Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
- DMX-200 Available To Patients Via Post-Trial Access Pathways
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
Later from Dimerix
- Dimerix Quarterly Activities Report and Appendix 4C
- Dimerix Presents at Bioshares Summit 2026
- Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
- Dimerix Receives US$10M Upfront Payment from Everest
- Appendix 4G and Corporate Governance Statement
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix